Document is current

Article History

Received: 17 June 2024

Revised: 22 November 2024

Accepted: 24 November 2024

First Online: 24 December 2024

Declarations

:

: KS reports research funding from Ono, MSD, Celgene, AbbVie, Takeda, Sanofi, Bristol-Myers Squibb, Janssen, Novartis, GSK, Chugai, Otsuka, Kyowa Kirin and Pfizer, and honoraria from Ono, Bristol-Myers Squibb, Sanofi and Janssen outside the submitted work. SI reports research funding from Ono, AbbVie, Takeda, Sanofi, Bristol-Myers Squibb, Daiichi-Sankyo, Janssen, Novartis, GSK, Chugai, Pfizer, Amgen and Shionogi, and honoraria from Takeda, Bristol-Myers Squibb, Sanofi, Pfizer, AstraZeneca and Janssen outside the submitted work. TF reports employment and ownership interest from GSK outside the submitted work. HK reports employment from GSK outside the submitted work. RF reports employment from GSK outside the submitted work. SW reports employment from GSK outside the submitted work. HN reports employment and ownership interest from GSK outside the submitted work. SRG reports employment from and financial equities in GSK outside the submitted work. BEK reports employment from and financial equities in GSK outside the submitted work.

: The study was done in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines following approval by ethics committees and institutional review boards at each study site. All patients provided written informed consent. This trial is registered at ClinicalTrials.gov (), identification number NCT03828292.